about
Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69.Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysisAirflow obstruction: is it asthma or is it COPD?Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergensGender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicineβ2-agonist therapy in lung disease.The clinical use of regenerative therapy in COPDThe effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections.Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298.The complex care of severe emphysema: role of awake lung volume reduction surgery.Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: a point of view.The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils.Biomarkers of lung damage associated with tobacco smoke in induced sputum.Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement.Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD.An update on bronchodilators in Phase I and II clinical trials.Comparative effectiveness of drugs for chronic obstructive pulmonary disease.Inhaled corticosteroids for chronic obstructive pulmonary disease.Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease.Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond.Defining phenotypes in COPD: an aid to personalized healthcare.Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?Umeclidinium for the treatment of chronic obstructive pulmonary disease.Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease.Canakinumab for the treatment of chronic obstructive pulmonary disease.QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease.Influence of ethnicity on response to asthma drugs.Novel glucocorticoid receptor agonists in the treatment of asthma.Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease.Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis.Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.Asthma management in a specialist setting: Results of an Italian Respiratory Society survey.
P50
Q24811040-FBBDFC91-8C35-4659-87F6-3B2FAFFBF7BBQ26795648-82686A2F-869B-4734-96F7-C00129495CE8Q28067052-767C8427-2552-4A4A-81C5-2EDC6FBEA7A5Q28385541-4E544D27-8EBF-47B2-9058-3501A522F010Q33715841-D38C3970-34E4-4321-BD7A-ACD0A5F1CD4EQ34324300-65A9F3E2-0906-497C-B21E-BF8F5E10A798Q34456011-74F4712D-32E7-4122-BBBB-AA7183D849ADQ34536485-A5DCC74B-F614-4B04-A605-FE26AE0C4933Q35082254-57886E9A-C6EA-447C-8731-212AF32F759CQ35620856-F0951D13-E1BA-413C-9ACA-324FA51E4DF4Q37001907-EC7478D1-3808-477C-93D8-9ABB55686626Q37046904-109FDC05-C15A-4B82-8263-351F2608CDCAQ37378323-4152EA21-FF4E-49F2-894E-12F999136C8AQ37553475-D78234E3-031D-4360-B012-85836A564FD6Q37602620-41204943-D2F7-4E65-B5AF-ADCB22B9A36FQ37679485-852922EF-7E35-4A61-88AC-93A602931F0EQ37988186-AEA7CD28-DD7F-4281-AB55-D0DB76AC52C4Q38037123-6E55E578-5565-4FC4-90C4-FED9AAC7D1CEQ38067720-71C995D5-E71E-4860-8823-6C01C5893A6AQ38153757-8B1618BD-8BD7-471D-8728-60AC22075A7BQ38199533-867428B2-C79E-44C0-9020-C22D07822FF9Q38205858-7035A7D1-52CC-4DF4-8138-5DF312982E93Q38208244-144AA319-B161-49E0-868E-7B2F1EDCF694Q38258537-F387221C-B5E3-4676-A044-FA6D2D42EE99Q38259862-D1A7AFC9-7E25-4A88-BE4C-D0DFF14E8B09Q38266325-4D800604-A46B-46A8-9D0E-056BDB39A483Q38306695-F2AA833E-250E-4EDD-B3F9-F2A3DFDA31D6Q38347142-A805F84A-2169-412C-8809-5CDD3DB33AE2Q38406157-2D719C5A-8979-4D4B-BB6B-F27EA5CA4EB8Q38494683-DF3A1C07-76B0-4268-B0B0-8B591808E40FQ38570469-04063059-372D-4FBF-8819-9E15CCB593AEQ38570714-032C3191-F2DA-4318-8CF1-33D8CF329294Q38608618-33E3E064-B6A6-4DA5-8715-7E5D825F081BQ38655574-AACA47C2-B59D-4BE6-A569-B1C9023C4526Q38740756-6055B961-6EEB-4025-9DC5-A664EB8ADDE8Q38753716-8017A183-0F64-43B0-BDB5-FAAD30D3E2FAQ38754002-EB4970E1-AC7D-4969-AE68-6CA72EC8B48FQ38832398-20246133-2165-41D1-A86A-DE26A57457EAQ38871993-BF9D06AD-51C2-45CE-9BAE-AA82C217AEA8Q38877581-712B6C31-4040-41F4-8A3E-8AF99162E649
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paola Rogliani
@ast
Paola Rogliani
@en
Paola Rogliani
@es
Paola Rogliani
@nl
Paola Rogliani
@sl
type
label
Paola Rogliani
@ast
Paola Rogliani
@en
Paola Rogliani
@es
Paola Rogliani
@nl
Paola Rogliani
@sl
prefLabel
Paola Rogliani
@ast
Paola Rogliani
@en
Paola Rogliani
@es
Paola Rogliani
@nl
Paola Rogliani
@sl
P106
P1153
6603386244
P21
P31
P496
0000-0001-7801-5040